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Summary
Objective: To develop an in vivo model for rapid assessment of cartilage aggrecan degradation and its pharmacological modulation.
Design: Tumor necrosis factor-a (TNFa) was injected intra-articularly (IA) in rat knees and aggrecan degradation was monitored at various
times following challenge. Articular cartilage was assessed for aggrecan content by Safranin O staining and by immunohistochemistry for
the NITEGE epitope. Synovial ﬂuids (SFs) were analyzed for sulfated glycosaminoglycans (GAGs) using the dimethylmethylene blue dye as-
say and for aggrecan fragments generated by speciﬁc cleavage at aggrecanase-sensitive sites by Western blot analysis with neoepitope an-
tibodies. Indomethacin, dexamethasone, and an aggrecanase inhibitor were evaluated for their ability to modulate TNFa-induced proteoglycan
degradation in vivo.
Results: (1) IA injection of TNFa in the knee joint of rats resulted in transient aggrecan degradation and release of aggrecanase-generated
aggrecan fragments from the articular cartilage into the SF; (2) a correlation was observed between histologically assessed depletion of ag-
grecan from the articular cartilage and the appearance of speciﬁc neoepitopes in the SF; (3) aggrecan degradation was inhibited by an ag-
grecanase inhibitor as well as by dexamethasone, but not by the non-steroidal anti-inﬂammatory drug (NSAID), indomethacin.
Conclusion: TNFa injection in the knee joints of rats results in rapid transient cartilage proteoglycan degradation, mediated by cleavage at the
aggrecanase sites. Biomarker read-out of speciﬁc neoepitopes in the SF enables the use of this mechanism-based model for rapid evaluation
of aggrecanase-mediated aggrecan degradation in vivo.
ª 2008 Osteoarthritis Research Society International. Published by Elsevier Ltd. All rights reserved.
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Osteoarthritis (OA) is characterized by the loss of the aggre-
gating proteoglycan, aggrecan, from articular cartilage. In
healthy cartilage, aggrecan, with its negative charge and
high water-binding capacity, provides the tissue with its
properties of compressibility and resilience. In human OA,
as in most animal models that resemble human disease,
aggrecan loss from the cartilage matrix is an early feature
of pathology1,2. Aggrecan depletion compromises cartilage
function and facilitates the progressive loss of collagen, ﬁ-
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627Loss of aggrecan is the result of enzymatic degradation
of the aggrecan core protein by aggrecanases, a disintegrin
and metalloproteinase with thrombospondin motif
(ADAMTS)-44 and ADAMTS-55e9 (reviewed in Ref. 10). It
was recently shown that ADAMTS-5 knock-out (KO) and
ADAMTS-4/-5 double KO, but not ADAMTS-4-KO mice
are resistant to surgically induced OA, suggesting that
ADAMTS-5 is the major aggrecanase in murine arthri-
tis11e14. Interestingly, ADAMTS-5-deﬁcient mice are pro-
tected not only against cartilage erosion, but against the
entire subsequent OA pathology, including osteophyte for-
mation and subchondral bone sclerosis15. It is still being de-
bated which aggrecanases are the key players in human
disease, but siRNA studies suggest a contribution of both
ADAMTS-4 and ADAMTS-5 in human cartilage explants16.
A critical role of the aggrecanases in the osteoarthritic pro-
cess is evident and thus inhibitors of these proteases have
potential for treatment of OA.
Numerous animal models that mimic aspects of the hu-
man disease have been developed. Spontaneous arthritis
in aging animals, or surgically, mechanically, and chemi-
cally induced models, as well as genetically modiﬁed mice
have been described (reviewed in Refs. 17,18). Appropriate
in vivo models are essential to gain insight concerning me-
diators and pathways involved in joint destruction, and to
evaluate pharmacological modulation of these pathways.
Since OA is a chronic progressive disease, a relevant ani-
mal model should demonstrate relatively slow progression,
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(DMOADs). However, the long time-course of disease de-
velopment in these models, along with time-intensive histo-
logical endpoints, precludes evaluating large numbers of
potential therapeutics for efﬁcacy. Thus, a need exists for
animal models of acute cartilage degradation that will permit
assessment of novel inhibitors for mechanism-related efﬁ-
cacy and potency in vivo, prior to evaluation in a more rel-
evant, but slow-developing chronic OA model. Ideally,
such a model should allow for a cartilage biomarker read-
out, in order to avoid dependence on labor- and time-inten-
sive histology as a primary outcome measure.
Here, we demonstrate that (1) intra-articular (IA) injection
of tumor necrosis factor-a (TNFa) in rat knee joint results in
transient aggrecan degradation and release of aggreca-
nase-generated aggrecan fragments from the articular car-
tilage into the synovial ﬂuid (SF); (2) there is a correlation
between histologically assessed depletion of proteoglycans
from cartilage and the appearance of speciﬁc neoepitopes
in the SF that allows for a fast biomarker read-out; (3) ag-
grecan degradation in this model is inhibited by an aggreca-
nase inhibitor, as well as by dexamethasone, but not the
NSAID, indomethacin, which is ineffective as a cartilage
protectant in man. Collectively, these data suggest that IA
TNFa injection in rat knees provides a mechanism-based
animal model of cartilage degradation that is suitable for
rapid assessment of aggrecan cleavage and putative chon-
droprotective agents in vivo.Materials and methodsMATERIALSRecombinant human (rh) TNFa was used, because there is a high degree
of homology between rat and human TNFa, and rat cells respond to rhTNFa.
rhTNFa containing an N-terminal his-tag was expressed and puriﬁed at
Pﬁzer. The construct has a pI of 7.4, and great care was taken to formulate
the puriﬁed cytokine in PBS at pH8.5, in order to avoid aggregation and in-
activation during storage and injection. Biological activity of TNFa was con-
ﬁrmed by testing its ability to induce aggrecan release from bovine nasal
cartilage explants, as described for interleukin-1 (IL-1)19 (not shown). Endo-
toxin levels were determined by a turbidimetric method, and were below
detectable levels of 0.016 EU. The monoclonal neoepitope antibody (Ab),
BC-3, that recognizes the new N-terminus, 374ARG, on aggrecan fragments
produced by cleavage at the Glu373eAla374 bond was licensed from Dr. Ca-
terson (Cardiff, Wales)20. Although BC-3 was raised to the human sequence
(ARGS), the Ab recognizes the rat sequence (ARGN). The polyclonal neoe-
pitope Abs that recognize the N-terminus 1565AGEG on aggrecan fragments
generated by cleavage at the Glu1564eAla1565 bond and the C-terminus
SELE1293 on fragments generated by cleavage at Glu1274eGly1275 were
developed, as described in Ref. 21. The polyclonal Ab against NITEGE373,
the C-terminus generated when aggrecanase cleaves aggrecan at the
Glu373eAla374 bond, and the neoepitope Ab, AF-28, that recognizes the
new N-terminus FFGV on fragments produced by cleavage at the Asn341e
Phe342 bond22, were a gift from Dr. Amanda Fosang (University of Mel-
bourne, Australia). Chondroitinase ABC lyase (Proteus vulgaris), keratanase
(Pseudomonas sp.) and keratanase II (Bacillus sp.) were from Seikugoku
(Kogyo, Japan). Hyaluronate lyase from Streptomyces hyalurolyticus, pa-
pain, indomethacin, and (soluble) dexamethasone were from Sigma, St.
Louis, MO. A selective aggrecanase inhibitor, reported by researchers at
DuPont Pharmaceuticals, ‘‘compound 11’’, a (2R)-N4-hydroxy-2-(3-hydroxy-
benzyl)-N1-[(1S,2R)-2-hydroxy-2,3-dihydro-1H-inden-1-yl]butanediamide de-
rivative23, was synthesized at Pﬁzer. We assessed compound 11 in
ADAMTS-4/-5 and matrix metalloproteinase (MMP) enzymatic assays9
and determined that it inhibited ADAMTS-4 and ADAMTS-5 with a Ki of
22.5 and 36.2 nM, respectively, while sparing MMP-1, MMP-2, MMP-3,
MMP-13, and MMP-14 (Ki> 10,000, 6170, 6120, 5950, and >10,000, re-
spectively). This compound blocked IL-1-induced aggrecanolysis in bovine
nasal cartilage19 with an IC50 of 370 nM and an IC90 of 4 mM.IN VIVO PROTOCOLSMale Sprague-Dawley rats (Harlan Laboratories, Indianapolis, IN),
weighing 300 g, received an IA injection containing TNFa in a volumeof 20 ml saline/0.1% bovine serum albumin (BSA). Rats injected with
20 ml saline/0.1% BSA alone served as vehicle controls. Pilot studies us-
ing Indian ink asserted that a 20-ml instillate was conﬁned to the synovial
space, and no leakage from the joint occurred (not shown). In addition,
pilot doseeresponse studies were performed, where rats were injected
IA with 0.01e20 mg TNFa and euthanized 16 h later for measurement of
glycosaminoglycan (GAG) release into the SF. TNFa doses between 0.1
and 20 mg resulted in SF GAG levels greater than in vehicle control joints,
with maximal release achieved with 5 mg TNFa and a plateau reached at
higher doses. Based on this, 10 mg TNFa were used for all studies de-
scribed herein. For time-course studies, n¼ 6e8 animals/group were eu-
thanized at various times following challenge with 10 mg TNFa or
vehicle. At necropsy, knee joints were lavaged with 100 ml saline using
an insulin syringe. Lavage ﬂuids were spun and frozen at 20C. Knee
joints were trimmed of muscle and connective tissue and collected in
10% neutral buffered formalin for histology.INHIBITOR STUDIESDrugs or vehicles were administered immediately prior to IA TNFa injec-
tion. Indomethacin and dexamethasone were administered p.o. in saline/
0.1% Tween 80. For intravenous (IV) studies, soluble dexamethasone
was administered in saline. The aggrecanase inhibitor was administered in
an IV infusion, in a vehicle consisting of 30% PEG400, 65% of 5% D-manni-
tol, and 5% 0.1 N NaOH.JOINT HISTOLOGY AND IMMUNOHISTOCHEMISTRYFollowing 6 days in 5% formic acid decalciﬁer, joints were cut into halves
in the frontal plane and parafﬁn-embedded. Three sections were cut from
each knee at 200 mm-steps and stained with Safranin O for evaluation of pro-
teoglycan content. A score was assigned based on intensity of Safranin O
staining by an observer blinded to the treatments received. Scores were 2,
1.5, 1, 0.5, or 0 for staining intensities ranging from full staining intensity
(2) to total loss of staining (0). The medial and lateral femoral condyles
and tibial plateaus were each scored separately. Total joint score was the
sum of these four scores and thus the maximal overall joint score was 8.
Data were analyzed using ManneWhitney U test for unpaired nonparametric
data.
Slides for immunohistochemistry were deparafﬁnized, rehydrated through
graded ethanol, pretreated with chondroitinase ABC (0.1 U/ml), washed in
TBSeTween, and unspeciﬁc antibody binding blocked using Protein Block.
Slides were incubated with primary antibody (NITEGE) at a 1/250 dilution.
Antibody binding was detected using the Envision Plus Alkaline Phospha-
tase system (DAKO), using BCIP/NBT (Roche) as the substrate, in the pres-
ence of levamisole to block endogenous alkaline phosphatase. Negative
controls contained no primary antibody but rabbit serum at an equivalent pro-
tein concentration.GAG ASSAYSF lavage samples were treated with hyaluronidase, 50 U/ml, at room
temperature until the sample was liqueﬁed. Samples were centrifuged, su-
pernatants collected and an equal volume of 500 mg/ml papain was added
(ﬁnal concentration 250 mg/ml). Samples were incubated for 2 h at 65C,
cooled to room temperature and spun24. GAG levels in SF were assessed
with 1,9-dimethylmethylene blue (DMMB), using shark chondroitin sulfate
as a standard25. Results are reported as mg GAG per ml lavage ﬂuid.NEOEPITOPE WESTERN BLOT ANALYSISFor analysis of aggrecan fragments generated by speciﬁc cleavage at
the aggrecanase cleavage sites, Glu373eAla374, Glu1274eGly1275, and
Glu1564eAla1565, aggrecan metabolites in lavage ﬂuids were enzymatically
deglycosylated with chondroitinase ABC (0.1 U/10 mg GAG) plus kerata-
nase (0.1 U/10 mg GAG)/keratanase II (0.002 U/10 mg GAG) for 4 h at
37C in buffer containing 50 mM sodium acetate, 0.1 M Tris/HCl, pH 6.5
(equal volumes of lavage ﬂuid and buffer with deglycosylating enzymes).
After digestion, samples were concentrated using a MicroCon concentrator
(Millipore, Bedford, MA) to a ﬁnal volume of 10 ml, loaded on ﬁve-well
4e12% gradient gels, separated by sodium dodecyl sulfate-polyacryl-
amide gel electrophoresis (SDS-PAGE) under nonreducing conditions,
transferred overnight to nitrocellulose and immunolocated with 1:1000 di-
lution of the speciﬁed antibody, as described in Ref. 9. Subsequently,
membranes were incubated with goat anti-rabbit IgG alkaline phosphatase
conjugate and aggrecan catabolites visualized by incubation with the ap-
propriate substrate (Promega Western blot alkaline phosphatase system).
Reactive aggrecan fragments were quantiﬁed by scanning densitometry.
Fig. 1. Time-course of cartilage aggrecan depletion. Rats were injected IA with 10 mg TNFa. At various times following challenge, groups of
rats were euthanized at the speciﬁed time-points and the knee joints were collected for Safranin O staining. ‘‘Time 0’’ represents uninjected
controls. Maximal depletion of aggrecan occurred 16 h after challenge, followed by partial replacement of proteoglycans, ﬁrst in the tibial
plateau (arrow, 24 h) and later in the femoral condyles. Each rat knee shown is representative for a group of n¼ 6.
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CARTILAGEJoints were taken for histology at various times following
IA TNFa and stained with Safranin O (Fig. 1). Compared
with staining of normal knee joints (time 0), a decrease in
Safranin O staining was observed as early as 4 h following
TNFa administration. Loss of staining continued progres-
sively over time, ﬁrst in the femoral condyles, and then in
the tibial plateaus, and was maximal by 16 h after TNFa.
At this time, loss of Safranin O staining in articular cartilage
was nearly complete, while fast green stain revealed an in-
tact collagen network (no ﬁbrillation at the cartilage surface
was observed). By 24 h following challenge, Safranin O
staining began to show gradual recovery of proteoglycans,
ﬁrst in the tibial plateau, and later in the femoral condyles.
Staining continued to increase through 72 h. Figure 2 com-
pares a TNFa-injected knee at the height of aggrecan de-
pletion, 16 h after TNFa injection, with an uninjected knee.
Signiﬁcant proteoglycan depletion from the cartilage of
TNFa-injected knees, as monitored by Safranin O staining
[Fig. 2(A)], was accompanied by generation of the NI-
TEGE373 neoepitope [Fig. 2(B)], indicating aggrecanase-
mediated cleavage at the Glu373/Ala374 bond within the
IGD of aggrecan.In order to enable statistical analysis, an additional study
was performed where joints from rats euthanized 6 h follow-
ing IA TNFa or saline were stained with Safranin O and pro-
teoglycan loss assessed by a blinded observer. Table I
shows that TNFaprovokedasigniﬁcant lossof proteoglycans
from the knee cartilage (P< 0.05 for total score). The aggre-
can loss was greatest in the femoral condyles (P¼ 0.007 for
the lateral and P¼ 0.019 for the medial condyle).TIME-COURSE OF APPEARANCE OF AGGRECAN FRAGMENTS
IN SFTo gain a better understanding of how the kinetics of
TNFa-induced aggrecan depletion correspond to the ki-
netics of aggrecan fragment release from cartilage,
groups of animals were euthanized at various times fol-
lowing challenge and synovial lavage ﬂuids were ana-
lyzed for GAG content or were pooled and subjected to
Western blot analysis for the ARG neoepitope on aggre-
can fragments generated by cleavage at Glu373/Ala374. IA
TNFa resulted in a time-dependent release of GAG into
the SF [Fig. 3(A)]. Levels were increased compared to
vehicle-injected controls by 6 h following challenge and
reached maximal levels very rapidly, between 8 and
16 h. By 24e48 h, levels fell dramatically, returning to
control levels. Analysis of these same samples by
Fig. 2. Assessment of aggrecanase-generated NITEGE neoepitope. Rats were injected IA with 10 mg TNFa, and 16 h later, knee joints were
collected for histology compared with time 0 (uninjected controls). (A) Safranin O staining shows proteoglycan depletion in the femoral con-
dyle; (B) immunohistochemistry reveals the presence of the NITEGE neoepitope in the depleted areas (blue signal, arrows). M¼meniscus.
630 A. M. Malfait et al.: TNFa-induced cartilage degradation in the ratWestern blot detected the presence of a 250-kDa ARGN-
containing fragment in response to TNFa. Quantitation by
scanning densitometry showed that the ARGN epitope in
SF increased with time between 6 and 16 h following
challenge [Fig. 3(B)]. After 24 h, immunoreactive frag-
ments were no longer detectable. No ARG-reactive frag-
ments were detected in the ﬂuids from vehicle controls
at any of the time-points. These data demonstrate a corre-
lation of GAG release and generation of the ARGN neo-
epitope over time, and provide further evidence that the
model is aggrecanase-dependent.EFFECT OF ANTI-INFLAMMATORY DRUGS ON AGGRECAN
DEGRADATIONRats were dosed orally with indomethacin (10 mg/kg) or
dexamethasone (1 mg/kg), or with vehicle as a control, im-
mediately prior to IA TNFa, and euthanized 16 h later. Ani-
mals injected IA with saline served as negative controls.
Indomethacin did not signiﬁcantly inhibit GAG release into
the SF in response to TNFa, whereas dexamethasone
caused essentially complete inhibition (Fig. 4).
To examine the doseeresponse for inhibition, rats were
injected IA with TNFa or vehicle. Immediately following
challenge, animals were treated by continuous IV infusion
for 16 h with various concentrations of dexamethasone or
with vehicle control. After 16 h, rats were euthanized andTable
Proteoglycan staining in rat knees, 6 h following IA administration of 10
staining by an observer blinded to the treatments received. Scores were
O staining intensity (2) to total loss of staining (0). The medial and lateral
The total joint score was the sum of these 4 scores and thus the maximal
U test for unpaired nonparametric data. Values shown are the median, wi
a two-sided ManneW
Femoral condyle
Lateral Medial
Control (n¼ 6) 2 (1e2) 1.5 (0e2)
TNFa (n¼ 7) 0.5 (0e2) 0 (0e1)
P¼ 0.007 P¼ 0.019joints lavaged. A dose-related inhibition of GAG release
into the SF was observed [Fig. 5(A)]. Maximal inhibition
(94%) was obtained with 0.1 mg/ml and the ED50 for inhibi-
tion of TNFa-induced GAG release was estimated from the
doseeresponse curve to be 0.006 mg/ml. Dexamethasone
also caused a dose-dependent inhibition of ARG neoepi-
tope generation in the SF [Fig. 5(B)]. The ED50 for inhibition
of ARG-generation was between 0.001 and 0.01 mg/ml
dexamethasone, similar to that for inhibition of GAG re-
lease. In order to evaluate the correlation between inhibition
of GAG release and inhibition of ARG neoepitope genera-
tion, Western blots from several separate studies were
quantiﬁed by scanning densitometry. Percent inhibition of
GAG release was plotted vs percent inhibition of ARG-gen-
eration [Fig. 5(C)], revealing a strong positive correlation be-
tween these two parameters.ASSESSMENT OF OTHER AGGRECAN NEOEPITOPES IN SFSIn addition to cleavage within the interglobular domain at
the Glu373eAla374 bond, aggrecanases cleave the aggre-
can core protein at four sites located in the chondroitin sul-
fate-rich region, between G2 and G3, at Glu1293/Gly1294,
Glu1478/Gly1479, Glu1584/Ala1585, and Glu1683/Leu1684. Be-
cause these have been shown to be preferred cleavage
sites in bovine and human aggrecan21,26, it can be ex-
pected that these epitopes will appear in SF before ARG-I
mg TNFa. A score was assigned based on intensity of Safranin O
2, 1.5, 1, 0.5, or 0 for staining intensities ranging from full Safranin
femoral condyles and tibial plateaus were each scored separately.
overall joint score was 8. Data were analyzed using ManneWhitney
th the range shown in parentheses. P-values were calculated using
hitney U test
Tibial plateau Total score
Lateral Medial
2 (1e2) 2 (1e2) 7 (5e8)
1 (0e2) 1 (0e2) 2 (1e7)
P¼ 0.106 P¼ 0.160 P¼ 0.014
Fig. 3. Time-course of TNFa-induced release of GAG and aggrecanase-generated fragments into the SF. Rats were injected IA with 10 mg
TNFa [-] or with vehicle [C] and euthanized at various times (1, 2, 4, 6, 8, 16, 24 and 48 h) following challenge. (A) GAG levels in the sy-
novial lavage ﬂuid were determined as mg GAG per ml of synovial lavage ﬂuid (n¼ 6 per groupSD); (B) Lavage ﬂuids of n¼ 6 rats were
pooled by group and analyzed for the presence of the ARG neoepitope. Western blots of pooled samples at different time-points are shown
(top) and the sum-density of the bands was measured by scanning densitometry (bottom).
631Osteoarthritis and Cartilage Vol. 17, No. 5containing fragments and thus may be useful for short term
studies. In an initial study, rats were injected IA with TNFa
and euthanized 6 h later. Lavage ﬂuids were pooled and as-
sessed by Western blot for SELE-containing fragments,
formed by cleavage at the SELE1293/1294GRGT bond, as
well as for ARG-containing neoepitopes [Fig. 6(A)]. The
SELE antibody provided a more sensitive read-out than
the ARG antibody, requiring smaller sample volumes and
enabling assessment of ﬂuids from individual animals. ToFig. 4. Effect of indomethacin and dexamethasone on TNFa-in-
duced proteoglycan degradation. Rats were injected IA with 10 mg
TNFa or with vehicle. Immediately prior to TNFa challenge, animals
were treated orally with dexamethasone (1 mg/kg), indomethacin
(10 mg/kg) or with vehicle. Sixteen hours following challenge, rats
were euthanized and the joints were washed with 100 ml saline.
GAG levels in the synovial lavage ﬂuid were measured, and results
are presented as mg GAG per ml of synovial lavage ﬂuid (n¼ 6 per
groupSD).conﬁrm that aggrecan fragments with the C-terminus
SELE1293 contained the N-terminus, ARG, and not the
MMP-generated N-terminus, FFGV22, replicate lanes were
run by SDS-PAGE on pooled ﬂuids from TNFa-challenged
rats and blots were cut and assessed by SELE, ARG and
FFGV Western analysis [Fig. 6(B)]. As expected, the
SELE-reactive fragment was recognized by the ARG anti-
body, but not by the FFGV antibody, conﬁrming that these
fragments contain an N-terminus, ARG, and a C-terminus,
SELE.
To assess the time-course for appearance of SELE and
AGEG, another sensitive neoepitope generated by cleav-
age at TAQE1584/1585AGEG, a separate study was con-
ducted where rats were injected TNFa or vehicle and
euthanized at various time-points. Synovial lavage samples
were analyzed for GAG levels and Western blot with the
neoepitope antibodies SELE1293 and 1585AGEG. No or
low levels of SELE- or AGEG-reactive fragments were de-
tected in SF from vehicle controls at any of the times eval-
uated (not shown), whereas both neoepitopes were rapidly
released into the SF in response to TNFa [Fig. 7(A)]. An
AGEG-reactive fragment was detected at 120 kDa by 4 h,
increasing over time through 8 h and then falling off in in-
tensity by 16 h. A similar time-course was seen for SELE-
reactive fragments. SELE fragments were detected as
a doublet at w250 kDa, the strongest band being the
smaller one, which corresponds with the fragment that
has 373ARGN as the N-terminus, and therefore more likely
to freely diffuse from the cartilage into the SF, as opposed
to the larger band that has the intact G1 at the N-terminus7.
Blots were quantiﬁed by scanning densitometry and plotted
as a percent of maximal levels in comparison with GAG
levels over time [Fig. 7(B)]. These data demonstrate that
both SELE- and AGEG-containing aggrecan fragments
are released over a similar time-course as GAG, suggest-
ing that they may serve as sensitive markers of cartilage
aggrecan degradation.
Fig. 5. Dose-related inhibition of TNFa-induced proteoglycan degradation by dexamethasone. Rats were injected IA with 10 mg TNFa or ve-
hicle. Immediately following TNFa challenge, animals were treated by continuous IV infusion with various doses of dexamethasone (0.001,
0.01, and 0.1 mg/ml, translating to doses of 1.67, 16.7, and 167 mg/kg/h, respectively) or with vehicle for the duration of the study and eutha-
nized 16 h following challenge. (A) GAG levels in the SF were determined on individual animals (n¼ 6/group) as mg GAG per ml lavage ﬂuid.
The mean for each Dex-treated group (n¼ 6) was then determined and % inhibition calculated compared to the mean GAG level in vehicle-
treated TNFa positive control group. These % inhibition values were then plotted to determine the ED50 for inhibition by Dex; (B) Lavage ﬂuids
of n¼ 6 rats were pooled and analyzed by Western blot for the presence of the ARG neoepitope; (C) ARG Western blots from several sep-
arate studies were quantiﬁed by scanning densitometry and percent inhibition of ARG epitope generation was plotted vs percent inhibition of
GAG release for each group.
632 A. M. Malfait et al.: TNFa-induced cartilage degradation in the ratEFFECT OF AN AGGRECANASE INHIBITORThe hydroxamate aggrecanase inhibitor, compound 11,
was evaluated for the ability to inhibit proteoglycan degra-
dation in this model. Since pharmacokinetic studies showed
that this compound has rapid clearance in rats, an IV bolus
of 5 mg/kg was administered 1 h prior to TNFa, followed by
continuous IV infusion (8650 ng/ml) until 6 h after TNFa
challenge when rats were euthanized. Throughout the
study, plasma levels of compound 11 were kept above
4 mM, the IC90 for this compound in blocking IL-1-induced
bovine cartilage degradation in vitro. Histological staining
of knee joints showed that the inhibitor prevented the loss
of Safranin O staining [Fig. 8(A)], demonstrating protection
from aggrecan loss. AGEG neoepitope levels in synovial la-
vages from individual rats were assessed by Western blot,
quantitated by scanning densitometry and the mean S.E.M.
determined [Fig. 8(B)], showing that AGEG levels were in-
creased in TNFa-injected knee joints and reduced back to
control levels in rats treated with the aggrecanase inhibitor
[Fig. 8(B)].Fig. 6. Assessment of aggrecanase-generated SELE neoepitope in
synovial lavage ﬂuids. Rats were injected IA with 10 mg TNFa, eu-
thanized 6 h following challenge and lavage samples pooled. (A)
Various volumes of lavage ﬂuid were assessed for SELE and
ARG-containing neoepitopes; (B) Replicate lanes were run by
SDS-PAGE and then blots cut and assessed by SELE, ARG and
FFGV neoepitope Western analysis.Discussion
This work describes an acute model of cartilage degra-
dation in the rat induced by IA TNFa injection. This cyto-
kine induced rapid, transient cartilage proteoglycan
degradation. The transient nature of the degradation is
likely due to the short duration of TNFa within the joint,as previous studies with 131I-IL-1 suggest that elimination
of cytokines from joint ﬂuid occurs in less than an
hour27. TNFa provoked primarily depletion of aggrecan
from the matrix with minimal collagenolysis. In fact, carti-
lage degradation was mild enough to allow for repair,
Fig. 7. Time-course of TNFa-induced release of aggrecan neoepi-
topes, SELE and AGEG. Rats were injected IA with 10 mg TNFa
and groups of rats were euthanized at various times following chal-
lenge. (A). Lavage ﬂuids of n¼ 6 rats were pooled and analyzed for
the presence of the SELE and AGEG neoepitopes by Western blot.
(B) GAG levels in of the SF lavages were measured and AGEG and
SELE blots were quantiﬁed by scanning densitometry. Data are
plotted as percent of maximal level vs time following TNFa
challenge.
633Osteoarthritis and Cartilage Vol. 17, No. 5with aggrecan restored toward control levels in the tibial
cartilage within 72 h after TNFa challenge. This is similar
to the events observed after IA administration of IL-1 in
rabbit knees, where recovery of proteoglycans occurred af-
ter the synthesis-inhibitory effects of IL-1 had worn off28,29.
Recently, it was elegantly demonstrated that cartilage deg-
radation in bovine cartilage explants is fully reversible in
the presence of aggrecanase but not MMP activity30. Inter-
estingly, recovery of proteoglycans after IA TNFa chal-
lenge was seen ﬁrst in the tibial plateau (where initial
depletion was least severe) before recovery in the femoral
condyles (where initial depletion was earliest and most se-
vere). This appears to be concordant with ﬁndings using
delayed Gadolinium-Enhanced Magnetic Resonance Im-
aging of Cartilage (dGEMRIC) to study repair of cartilage
explants, in which cartilage regions most severely de-
pleted by IL-1 showed negligible GAG accumulation 3
weeks later, whereas those regions affected the least by
IL-1 showed the greatest recovery31. Extending dGEMRIC
studies to a reversible in vivo model of aggrecan depletion
such as the one described here may be valuable for in
vivo study of cartilage repair processes.
IA administration of IL-1 has been extensively studied in
several species, including rabbits28,29,32e35, mice36, andrats37e39 and consistently resulted in cartilage catabolism.
IA injection of TNFa has been much less studied34. A recent
paper described that both IL-1b and TNFa elicited re-
sponses in the rat knee, including soft tissue inﬂammation
and cartilage matrix loss, but only IL-1 drove skeletal re-
sorption. Overall, IL-1b appeared to be more potent than
TNFa in inducing these effects39. However, in developing
an in vivo tool for rapid screening of chondroprotective
drugs, a model characterized by a rapid onset, but mild
and reversible cartilage degradation, as is observed with
TNFa, offers a signiﬁcant advantage.
Ideally, an in vivo model for screening pharmacological
modulation of cartilage degradation should use a biomarker
in a readily accessible ﬂuid, such as blood or SF, as an end-
point read-out in order to avoid the long delay required for
histological processing. The current work demonstrates
that GAG levels in the SF provide a good indicator of pro-
teoglycan loss from cartilage. However, the overall amount
of GAG released into the SF cannot be determined from
these levels measured at discrete time-points due to the dy-
namic nature of GAG appearance and loss from the ﬂuid
over the course of the study. A seminal study by Dingle
and co-workers describes the IA injection of partially puri-
ﬁed catabolin/IL-1 in rabbits and demonstrated subsequent
loss of GAG from the cartilage and concomitant increase in
SF GAG27. Our data not only conﬁrm these early studies in
another species but extend this work by demonstrating that
GAG levels in the SF correspond with the appearance of
aggrecan fragments cleaved speciﬁcally at the aggreca-
nase sites that can be used to monitor proteoglycan degra-
dation and loss from the cartilage matrix, as well as efﬁcacy
of inhibitors in preventing this degradation.
A major ﬁnding was that IA injection of TNFa in rats re-
sults in the generation of aggrecan fragments formed by
cleavage at the Glu373/Ala374 aggrecanase site. Aggrecan
fragments with the N-terminus ARGS (ARGN in rat aggre-
can) have also been detected in the SF of patients with
OA, inﬂammatory joint disease and joint injury9,40,41. Evalu-
ation of SFs in the rat over a 48-h period following IA injec-
tion with TNFa indicated that there is a coordinate increase
in levels of ARGN-containing fragments formed by speciﬁc
cleavage at the aggrecanase site and proteoglycan catabo-
lites as monitored by GAG levels, which correspond with
proteoglycan loss from the cartilage.
Experiments with inhibitors demonstrate the potential util-
ity of the TNFa rat model as an in vivo screening tool. The
aggrecanase inhibitor study demonstrated the ability of the
compound to block cartilage aggrecan depletion as as-
sessed by Safranin O staining, and the release of aggrecan
fragments into the SF, whereas a broad spectrum nanomo-
lar MMP-inhibitor that does not inhibit ADAMTS-4/
ADAMTS-5, XS309 (described in Ref. 9), was ineffective
in the model, at plasma concentrations of up to 30 mM (Ar-
ner and Tortorella, unpublished data). In addition, this study
demonstrated the utility of SF AGEG neoepitope levels as
a rapid biomarker read-out of inhibitor efﬁcacy. The model
also differentiated standard arthritis drugs, which are known
to reach the joint and provide anti-inﬂammatory effects, for
their ability to inhibit TNFa-induced cartilage degradation.
The NSAID, indomethacin, whose anti-inﬂammatory mech-
anism involves inhibition of prostaglandin production, was
ineffective in blocking cartilage degradation in this model.
In contrast, dexamethasone, which inhibits TNFa signaling
through TNFR1 by affecting the regulation of mitogen-acti-
vated protein (MAP) kinases42, caused a dose-related inhi-
bition of proteoglycan release into the SF that showed
a strong correlation with inhibition of the aggrecanase-
Fig. 8. Inhibition of TNFa-induced aggrecan degradation with an aggrecanase inhibitor. Rats were injected IA with vehicle or 10 mg of TNFa,
with or without continuous IV infusion of an aggrecanase inhibitor. At 6 h following challenge, rats were euthanized, synovial lavage ﬂuids
collected and knee joints taken for histology. (A) Knee joints were stained with Safranin O. Shown is the median representative of n¼ 5
for control, n¼ 7 for TNFa, and n¼ 6 for TNFþ drug groups; (B) synovial lavage ﬂuids of individual rats were analyzed for the presence
of aggrecan fragments with the new N-terminus AGEG. Western blots (shown on top) were quantiﬁed by scanning densitometry and data
are presented as mean S.E.M. of antibody reactivity.
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that, due to the speciﬁc stimulus being used (i.e., TNFa),
there are obvious limitations to the predictability of this
model for compound efﬁcacy in a chronic model of OA.
For example, we have found that in the rat medial meniscal
tear (MMT) model43 an aggrecanase inhibitor is very effec-
tive, whereas dexamethasone is totally ineffective (unpub-
lished data), which may suggest that the MMT model is
not TNFa-driven. Thus, compounds found to be efﬁcacious
in the acute TNFa model would ultimately need to be tested
in a chronic disease model. Nevertheless, the TNFa rat
model provides a rapid upstream screen for prioritizing
pharmacological agents for testing in these more time-
and labor-intensive models.
In summary, IA administration of TNFa in rat knee joints
results in rapid, reversible aggrecan depletion from the car-
tilage. The fast onset of cartilage degradation and the ease
of read-out in the SF via a biomarker that is speciﬁc for ag-
grecanase activity and correlates with cartilageproteoglycan loss enables rapid assessment of in vivo car-
tilage catabolism and may provide insight into potential in-
hibitor mechanism of action. In addition, the reversibility of
aggrecan depletion may permit the use of this model for
the study of cartilage repair as well as degradation.Conﬂict of interest
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